Ritter Pharmaceuticals Inc (NASDAQ:RTTR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Other research analysts have also issued reports about the stock. Chardan Capital boosted their price objective on shares of Ritter Pharmaceuticals from $3.00 to $3.30 and gave the stock a “buy” rating in a research note on Tuesday, October 25th. Aegis restated a “buy” rating and set a $9.00 price objective on shares of Ritter Pharmaceuticals in a research note on Tuesday, October 18th. Finally, Maxim Group lowered their price objective on shares of Ritter Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, November 7th.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.44 on Friday. The company has a 50-day moving average of $2.25 and a 200 day moving average of $1.71. The firm’s market cap is $20.94 million. Ritter Pharmaceuticals has a 52-week low of $0.98 and a 52-week high of $3.26.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.09. On average, equities research analysts anticipate that Ritter Pharmaceuticals will post ($1.59) EPS for the current year.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Baker BROS. Advisors LP acquired a new stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 400,000 shares of the company’s stock, valued at approximately $672,000. Baker BROS. Advisors LP owned about 4.66% of Ritter Pharmaceuticals as of its most recent filing with the SEC.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

5 Day Chart for NASDAQ:RTTR

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.